Orexigen Therapeutics, Inc. - Product Pipeline Review - Q4 2010

GlobalData, November 2010, Pages: 52

Orexigen Therapeutics, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Orexigen Therapeutics, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Orexigen Therapeutics, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Orexigen Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Orexigen Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Orexigen Therapeutics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Orexigen Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Orexigen Therapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Orexigen Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Orexigen Therapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Orexigen Therapeutics, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Orexigen Therapeutics, Inc. Snapshot
Orexigen Therapeutics, Inc. Overview
Key Information
Key Facts
Orexigen Therapeutics, Inc. – Research and Development Overview
Key Therapeutic Areas
Orexigen Therapeutics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Orexigen Therapeutics, Inc. – Pipeline Products Glance
Orexigen Therapeutics, Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Orexigen Therapeutics, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Orexigen Therapeutics, Inc. – Drug Profiles
Contrave
Product Description
Mechanism of Action
R&D Progress
Empatic
Product Description
Mechanism of Action
R&D Progress
Fluoxetine + Naltrexone
Product Description
Mechanism of Action
R&D Progress
OREX-004
Product Description
Mechanism of Action
R&D Progress
Orexigen Therapeutics, Inc. – Pipeline Analysis
Orexigen Therapeutics, Inc. – Pipeline Products by Therapeutic Class
Orexigen Therapeutics, Inc. Pipeline Products By Target
Orexigen Therapeutics, Inc. – Pipeline Products by Route of Administration
Orexigen Therapeutics, Inc. – Pipeline Products by Molecule Type
Orexigen Therapeutics, Inc. – Recent Pipeline Updates
Orexigen Therapeutics, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
OREX-003
Orexigen Therapeutics, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Oct 04, 2010: Orexigen Announces Upcoming Data Presentations At 28th Annual Scientific Meeting Of Obesity Society
Sep 02, 2010: Orexigen Partners With Takeda To Commercialize Contrave In North America
Aug 03, 2010: Orexigen Announces Publication Of Results From COR-BMOD Study In Journal Obesity
Jul 29, 2010: Orexigen Announces Publication Of COR-I Phase III Study Of Contrave In Lancet
Jun 26, 2010: Orexigen Announces Results Of Contrave In Overweight And Obese Patients With Major Depression
Jun 25, 2010: Orexigen Presents New Data On Contrave In Obese Patients With Type 2 Diabetes
Jun 23, 2010: Orexigen Announces Date Of FDA Advisory Committee Review Of Contrave For Treatment Of Obesity
Jun 17, 2010: Orexigen Announces PDUFA Date For Review Of Contrave New Drug Application
Jun 01, 2010: Orexigen Announces FDA Acceptance Of Contrave New Drug Application For Treatment Of Obesity
Mar 31, 2010: Orexigen Submits Contrave NDA To FDA For Treatment Of Obesity
Financial Deals Landscape
Orexigen Therapeutics, Inc., Deals Volume Summary, 2004 to YTD 2010
Orexigen Therapeutics, Inc., Deals Summary By Region, 2004 to YTD 2010
Orexigen Therapeutics, Inc., Deals Summary, 2004 to YTD 2010
Orexigen Therapeutics, Inc. Detailed Deal Summary
Venture Financing
Orexigen Therapeutics Secures $30 Million In Series C Financing
Orexigen Therapeutics Secures $35 Million In Series B Financing
Orexigen Therapeutics Secures $11 Million In Series A Financing
Equity Offering
Orexigen Therapeutics Completes Public Offering Of $86 Million
Orexigen Therapeutics Completes Public Offering Of $81 Million
Orexigen Therapeutics Completes Initial Public Offering For $84 Million
Orexigen Therapeutics Files Shelf Registration Statement For Public Offering Of $150 Million
Licensing Agreements
Orexigen Therapeutics Enters Into Licensing Agreement With GlaxoSmithKline
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Charter Schools - Global Outlook
• eLEARNING - Global Strategic Business Report
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• Aerospace and Defense Industry - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• North America – Smart Weapons Markets and Technologies Outlook – 2013-2020
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Private Tutoring - Global Strategic Business Report